Trevor Allred Analyst PerformanceSenior Analyst, Biotechnology at OppenheimerTrevor Allred is a stock analyst at Oppenheimer focused in the medical sector, covering 9 publicly traded companies. Over the past year, Trevor Allred has issued 17 stock ratings, including buy and hold recommendations. While full access to Trevor Allred's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Trevor Allred's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings17 Last 0 YearsBuy Recommendations94.12% 16 Buy RatingsCompanies Covered9 Unique Companies Ratings Distribution17RatingsDistribution of strong buy, buy, hold, and sell ratings by Trevor Allred.RatingPercentageCount Strong Buy0.0%0 ratings Buy94.1%16 ratings Hold5.9%1 ratings Sell0.0%0 ratingsOut of 17 total stock ratings issued by Trevor Allred at Oppenheimer, the majority (94.1%) have been Buy recommendations, followed by 5.9% Hold.Best & Worst CallsThis analyst does not have any ratings with enough history to determine best and worst calls.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ9 companiesTrevor Allred, an analyst at Oppenheimer, currently covers 9 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical8 companies88.9%Manufacturing1 company11.1%Trevor Allred of Oppenheimer specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE5 companies55.6%MED - DRUGS1 company11.1%MED - GENERIC DRG1 company11.1%LARGE CAP PHARMA1 company11.1%PHARMACEUTICAL PREPARATIONS1 company11.1% About Trevor AllredTrevor Allred is a Senior Analyst covering Biotechnology. Trevor has been with Oppenheimer since 2019. Prior to joining Oppenheimer, Trevor spent over five years working as a Clinical Laboratory Scientist before pursuing his MBA. Trevor holds a Bachelor of Science degree in Medicinal Chemistry and Molecular Pharmacology from Purdue University, and a Master in Business Administration from Indiana University’s Kelley School of Business. Trevor Allred's Ratings History at Oppenheimer Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsDNTHDianthus Therapeutics3/9/2026Boost Price Target$82.51$145.00Outperform$0.0000.00% ROITBPHTheravance Biopharma3/5/2026Downgrade$13.54Market Perform$0.0000.00% ROILGNDLigand Pharmaceuticals2/27/2026Boost Price Target$197.55$277.00Outperform$0.0000.00% ROIBBIOBridgeBio Pharma2/25/2026Lower Price Target$65.76$81.00Outperform$0.0000.00% ROIBBIOBridgeBio Pharma2/13/2026Boost Price Target$77.08$83.00Outperform$0.0000.00% ROIDSGNDesign Therapeutics1/7/2026Initiated Coverage$8.82$18.00Outperform$0.0000.00% ROILEGNLegend Biotech1/7/2026Initiated Coverage$20.98$75.00Outperform$0.0000.00% ROIPVLAPalvella Therapeutics12/15/2025Reiterated Rating$89.02$200.00Outperform$0.0000.00% ROITBPHTheravance Biopharma12/3/2025Initiated Coverage$18.43$27.00Outperform$0.0000.00% ROIPVLAPalvella Therapeutics11/11/2025Reiterated Rating$77.85Outperform$0.0000.00% ROILGNDLigand Pharmaceuticals11/3/2025Boost Price Target$191.19$250.00Outperform$0.0000.00% ROIPVLAPalvella Therapeutics9/9/2025Initiated Coverage$55.02$85.00Outperform$0.0000.00% ROILGNDLigand Pharmaceuticals9/3/2025Boost Price Target$165.95$190.00Outperform$0.0000.00% ROIINVAInnoviva8/11/2025Initiated Coverage$18.34$45.00Outperform$0.0000.00% ROILGNDLigand Pharmaceuticals7/30/2025Boost Price Target$134.13$162.00Outperform$0.0000.00% ROIMBXMBX Biosciences7/16/2025Initiated Coverage$13.40$38.00Outperform$0.0000.00% ROILGNDLigand Pharmaceuticals5/9/2025Boost Price Target$106.35$145.00Outperform$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James FinancialStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
